Epistaxis During Antiplatelet and Anticoagulant Therapy in Patients with Cardiovascular Disease: Clinical Dilemmas, Guideline Comparison, and a Personalized Management Algorithm
Year: 2026
Type: article
Study design: Systematic Review
Abstract: Background and Objective. Epistaxis is a frequent bleeding manifestation in patients receiving antithrombotic therapy, and its management falls between otolaryngology and cardiology guidance. We aimed to translate the evidence into an operational framework for joint decisions. Methods. PubMed/MEDLINE, Scopus, Embase, and the Cochrane Library were searched (January 2015 through August 2026), current ESC, ACC/AHA, EHRA, AAO-HNS, and SFORL guidance were analyzed, and national clinical protocols of different countries were screened; 67 sources were included. Results. Direct oral anticoagulants were consistently associated with fewer clinically relevant epistaxis events than warfarin, and minor epistaxis led to permanent anticoagulant discontinuation more often than minor bleeding at other sites. No guideline defines epistaxis severity, and guidance diverges on protected dual antiplatelet therapy, bleeding-risk assessment, and the sequence of local hemostasis and drug interruption. We propose a three-tier severity classification (minor, clinically relevant non-major, major) informed by ISTH and BARC definitions, a pragmatic thrombotic risk stratification, and an algorithm with agent-specific decisions. Conclusions. In minor and most clinically relevant non-major episodes, antithrombotic therapy can usually be continued while local hemostasis is achieved; interruption, de-escalation, or reversal should be individualized and reserved for uncontrolled or major bleeding. Effective local hemostasis can help avoid unnecessary interruption of antithrombotic therapy, and otolaryngologists should be part of multidisciplinary teams managing such bleeding.
Source: Diseases
Authors: Zhanetta Mukanova, Sholpan Zhangelova, Dina Kapsultanova, Kanatbek Mukanov, Zhanar Nurbay, Gulzada Nurgaliyeva, Aigyul Izhanova, Aizhan Almukhanova, Galiya Zhansarina, Meiramgul Tokbulatova, Assel Issabekova, Zhanar Toktarova, Akhmetzhan Sugraliyev, Farida Rustamova, Rimma Suatbayeva, Assel Imangaliyeva, Friba Nurmukhammad
Institutions: Kazakh National Medical University, Astana Medical University
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Keywords: epistaxis, antithrombotic therapy, antiplatelet therapy, anticoagulation, direct oral anticoagulants, warfarin, bleeding risk assessment, thrombotic risk stratification, local hemostasis, anticoagulation interruption, anticoagulant reversal, dual antiplatelet therapy, multidisciplinary management
Open Access status: gold
Estimated APC paid: $2,172
OpenAlex ID: W7225875991
